Diagnostic-Consultative Center Alexandrovska EOOD
- Address
- Triaditsa, Ulitsa Sveti Georgi Sofiyski 1, 1431 Sofia, Bulgaria
Cardiovascular Diseases
At Diagnostic-Consultative Center Alexandrovska EOOD in Sofia, the cardiovascular research portfolio focuses on major conditions such as atrial fibrillation and heart failure, especially HFmrEF and HFpEF with systemic inflammation. These trials are designed to assess new treatment options and compare them with established care to better prevent serious complications.
- Preventing stroke and systemic embolism in people with atrial fibrillation
- Evaluating therapies for heart failure with preserved or mildly reduced ejection fraction
- Testing approaches aimed at lowering cardiovascular death and heart failure-related events
The site contributes to studies that aim to improve how cardiovascular diseases are treated and managed in everyday clinical practice.
Eye Diseases
The eye disease research at this center is centered on vision problems linked to macular edema secondary to retinal vein occlusion. The trials are exploring whether newer treatment strategies can help preserve or improve vision while maintaining safety and effectiveness.
- Studying treatment for macular edema caused by retinal vein occlusion
- Assessing changes in best-corrected visual acuity after treatment
- Comparing a newer eye therapy with an established option to support vision care
This work reflects a practical focus on improving outcomes for people with retinal conditions that can threaten central vision.
Clinical Research Focus at the Site
Across its small but targeted trial portfolio, Diagnostic-Consultative Center Alexandrovska EOOD is involved in research spanning cardiovascular disease and ophthalmology. The studies are aimed at testing whether new therapies can outperform or match current treatments, with attention to both effectiveness and patient benefit.
- Comparing new and standard treatments in heart disease
- Exploring better prevention strategies for clot-related complications
- Supporting advances in the treatment of retinal swelling and vision loss
With research activity led by a small investigator team, the site contributes to clinically relevant studies that address common and serious conditions affecting the heart and eyes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Biogen Idec Research Limited1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diagnostic-Consultative Center Alexandrovska EOOD
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 1 | Unknown | 2023-09-13 | 2023-09-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.